Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Jonathan Lieber, Chief Financial Officer of Rallybio, will present a corporate overview at the 2024 Jones Healthcare Seaside Summit on July 15, 2024 at 8:00 a.m. PT (11:00 a.m. ET) in Encinitas, CA.

A live webcast of the presentation will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation.

About Rallybio

Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in New Haven, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn and Twitter.

Investors Samantha Tracy Rallybio Corporation (475) 47-RALLY (Ext. 282) investors@rallybio.com

Kevin Lui Precision AQ (212) 698-8691 Kevin.Lui@precisionaq.com

Media Victoria Reynolds Mission North (760) 579-2134 rallybio@missionnorth.com

Rallybio (NASDAQ:RLYB)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Rallybio Charts.
Rallybio (NASDAQ:RLYB)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Rallybio Charts.